Tower Research Capital (TRC)’s Pharvaris PHVS Stock Holding History

Tower Research Capital (TRC)’s Portfolio PHVS Stock Details PHVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.72K	Sell	238 -233	-49%	-$6.22K	﹤0.01%	4041
2025 Q4	$13.1K	Buy	+471	New	+$11.3K	﹤0.01%	3430
2023 Q1	–	Sell	-12,993	Closed	-$146K	–	6178
2022 Q4	$146K	Buy	12,993 +9,533	+276%	+$50.1K	0.01%	1535
2022 Q3	$26K	Buy	+3,460	New	+$54.1K	﹤0.01%	3723
2022 Q2	–	Sell	-77	Closed	-$1K	–	6423
2022 Q1	$1K	Buy	+77	New	+$1.36K	﹤0.01%	5836
2021 Q4	–	Sell	-211	Closed	-$4K	–	6461
2021 Q3	$4K	Sell	211 -350	-62%	-$5.99K	﹤0.01%	4992
2021 Q2	$11K	Buy	+561	New	+$12.7K	﹤0.01%	4334

Other funds holding PHVS

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

EFM

EQT Fund Management Luxembourg $1.02B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Tower Research Capital (TRC)'s PHVS Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Pharvaris (PHVS) stake by 49% in Q1 2026, selling an estimated $6.22K and leaving 238 shares worth $6.72K. The position accounts for ﹤0.01% of the portfolio, ranked #4041.

Tower Research Capital (TRC) first reported a position in PHVS in Q2 2021 and has held it in 7 quarters since. The position peaked at $146K in Q4 2022. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

Tower Research Capital (TRC) held 238 shares of Pharvaris worth $6.72K as of Q1 2026.
Tower Research Capital (TRC) sold 233 Pharvaris shares in Q1 2026, an estimated $6.22K.
Pharvaris made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4041 holding.
Tower Research Capital (TRC) first reported a position in Pharvaris in Q2 2021 and has held it in 7 quarters since.
Tower Research Capital (TRC)'s Pharvaris position peaked at $146K in Q4 2022.
110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.